Indaptus Therapeutics Inc
Change company Symbol lookup
Select an option...
INDP Indaptus Therapeutics Inc
FUSN Fusion Pharmaceuticals Inc
RDUS Schnitzer Steel Industries Inc
ALEC Alector Inc
LZM Lifezone Metals Ltd
LMRMF Lomiko Metals Inc
SOXL Direxion Daily Semiconductor Bull 3X Shares
OXSQ Oxford Square Capital Corp
BAER Bridger Aerospace Group Holdings Inc
CMRA Comera Life Sciences Holdings Inc
Go

Health Care : Biotechnology |
Company profile

Indaptus Therapeutics, Inc. is a clinical biotechnology company. The Company is focused on enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas. It designs its approach by targeting specific tumor or viral antigens. Its lead candidate, Decoy20, through pre-clinical development. Its platform is based on the hypothesis that require anti-tumor immunotherapy to activate both innate and adaptive cellular immunity in both tumors and immune organs. Its approach uses multi-targeted package of bacterial pathogen-associated molecular patterns (PAMPs), in the form of attenuated and killed, intact but non-pathogenic bacteria delivered intravenously. Its intravenous therapeutic candidates target the liver, spleen, and leaky vasculature of tumors, producing immune activation in an immune organ, as well as a common site for primary and metastatic cancer and hepatitis B virus (HBV) infection.

Closing Price
$2.46
Day's Change
-0.25 (-9.23%)
Bid
--
Ask
--
B/A Size
--
Day's High
2.85
Day's Low
2.40
Volume
(Light)
Volume:
27,284

10-day average volume:
40,136
27,284

Rivian delivers 7,946 vehicles in first quarter, says it's on pace to meet annual production goal

8:49 am ET April 3, 2023 (MarketWatch)
Print

Rivian Automotive Inc. (RIVN) produced 9,395 vehicles at its Normal, Ill. manufacturing facility during the first quarter, the electric-vehicle company announced Monday morning. Rivian also delivered 7,946 vehicles in the period. Analysts tracked by FactSet were expecting about 8,000 deliveries for the quarter, based on three estimates. Rivian described the delivery and production figures as being in line with its own expectations. The company expects that it's on pace to meet its production goal of 50,000 units for the year. Rivian will post its first-quarter results after the closing bell on May 9. Shares of the company were off about 1% in premarket trading Monday.

-Emily Bary

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

	

(END) Dow Jones Newswires

April 03, 2023 08:49 ET (12:49 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.